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During pancreatic development insulin+ cells co-express the transcription factors MafB and Pax6, and transition from a MafA− to MafA+ state.
To examine the role of Pax6 and MafB in the development of β-cells, we analyzed embryonic pancreata from Pax6- and MafB-deficient mice.
Pax6 deficiency, as manifest in the Pax6Sey–Neu allele, reduced not only the number of cells expressing insulin or glucagon, but also the number of
MafB, PDX-1 and MafA expressing cells. We show that MafB can directly activate expression of insulin and glucagon, and a MafB protein
engineered to contain N248S mutation in the MafB (krENU) results in significantly reduced activation. Furthermore, pancreata from MafB deficient
(krENU/krENU) mice exhibited reduced number of cells expressing insulin, glucagon, PDX-1 and MafA, with only a minor reduction in MafB
expressing cells. MafB deficiency does not affect endocrine specification but does affect the lineage commitment of the endocrine cells and their
maturation. Similar to Pax6 deficient mice, MafB deficient mice showed reductions both in insulin and glucagon expressing cells and in the ability
of MafB and PDX-1 expressing cells to activate expression of these hormones. However, MafB deficient mice exhibited no effect on Pax6
expression. These results suggest that MafB may function as a downstream mediator of Pax6 in regulating the specification of insulin and
glucagon expressing cells. Interestingly, the remaining insulin+ cells in these knockouts preferentially express Hb9, suggesting the existence of an
alternate pathway for the generation of insulin expressing cells, even in the absence of Pax6 and MafB function. Thus, Pax6 acts upstream of
MafB, which in turn may trigger the expression of insulin and regulate the PDX-1 and MafA expression required for β-cell maturation.
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To develop reliable sources of glucose-responsive β-cells for
the treatment of diabetes, it is essential to understand how β-
cells form during development. The pancreas develops as a
dorsal and ventral evagination from the developing foregut that
expresses the homeodomain transcription factor PDX-1
(Edlund, 2002; Leonard et al., 1993; Miller et al., 1994; Ohlsson
et al., 1993). PDX-1 is essential for the normal proliferation and⁎ Corresponding author. Research Division, Joslin Diabetes Center, One
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doi:10.1016/j.ydbio.2007.12.009differentiation of embryonic pancreatic precursors (Edlund,
2002; Jonsson et al., 1994; Offield et al., 1996). Another
transcription factor, Ngn3, regulates the differentiation of
endocrine cells (Gradwohl et al., 2000). In addition, several
other transcription factors play critical roles in both pancreatic
development and endocrine differentiation (Collombat et al.,
2006; Grapin-Botton and Melton, 2000; Jensen, 2004; Kim and
MacDonald, 2002; Murtaugh, 2007). For example, transcription
factors Arx and Pax4 play critical roles in regulating specifica-
tion of endocrine progenitors towards α- or β- and δ-cell fates
(Collombat et al., 2005, 2006, 2007). Pax6 is required for
maintaining these hormone-expressing cells and for regulating
specification of ghrelin-expressing ε-cells (Ashery-Padan et al.,
2004; Heller et al., 2005; Wang et al., 2004). In addition,
444 W. Nishimura et al. / Developmental Biology 314 (2008) 443–456members of the Nkx and Maf families regulate the differentia-
tion of hormone positive cells.
The identification of MafA as a β-cell specific basic leucine
zipper (bZIP) transcription factor has initiated the systematic
characterization of Maf factors in pancreatic development and
in β-cell function (Olbrot et al., 2002; Kataoka et al., 2002;
Matsuoka et al., 2003). MafA (formerly known as RIPE3b1) is a
glucose-responsive insulin gene transcription factor that binds
to the insulin Maf Response Element (MARE) and activates
insulin gene expression (Sharma and Stein, 1994; Olbrot et al.,
2002; Kataoka et al., 2002; Matsuoka et al., 2003). Another Maf
factor, MafB [also known as Kreisler (Krml1/MafB)], is
expressed in pancreatic endocrine cells and regulates differ-
entiation of several cell types (Eichmann et al., 1997;
Manzanares et al., 1997; Moriguchi et al., 2006; Sieweke et
al., 1996). The gene was first identified as the locus mutated in
the Kreisler (kr) mouse, and a second ethylnitrosourea (ENU)
induced mutation [krENU (also known asMafBENU)] in this gene
has been described (Cordes and Barsh, 1994). MafB, expressed
only in α-cells in adults, is expressed in the insulin positive cells
during pancreatic development (Artner et al., 2006; Nishimura
et al., 2006). We proposed that endocrine progenitors after
committing to the insulin positive lineage continue a further
differentiation/maturation process. Early insulin+ cells express
MafB, and following the induction of PDX-1, mature into
insulin+ and MafA+ cells (Nishimura et al., 2006). MafA
deficient Mice have normal pancreatic islets at birth, but the
ratio of β to α cells gradually reduce after birth, resulting in
glucose intolerance by 8–12 weeks (Zhang et al., 2005). This
phenotype suggests a critical role of MafA in the maturation
step required for the function and survival of β-cells. The
importance of this maturation step is highlighted by a recent
publication on the differentiation of human ES cells into
insulin+ cells (D'Amour et al., 2006). Although these insulin+
cells expressed MafB, they did not maintain the expression of
PDX-1 and did not secrete insulin in response to glucose
(D'Amour et al., 2006). We hypothesize that these cells may not
have switched from MafB+ MafA− to MafB− MafA+ state. It is
likely that the lack of MafA expression prevents early insulin+
cells from expressing the downstream targets of MafA that are
required for the insulin synthesis and secretion (Kato et al.,
2006; Wang et al., 2007). Thus, elucidation of the mechanisms
that regulate the conversion of insulin+ cells into mature
functional β-cells should facilitate our ability to generate
glucose-responsive, insulin-producing cells for cell-based
diabetes therapy.
In the present study, we characterized the roles of Pax6 and
MafB in the differentiation of insulin expressing cells. Loss of
either Pax6 or MafB function results in reduced numbers of
cells that express insulin, glucagon, PDX-1 or MafA, and
decreases the ability of MafB+ and PDX-1+ cells to express
insulin. Our results suggest that MafB may function as a
downstream mediator of Pax6 in regulating the formation of
insulin and glucagon positive cells. We present data supporting
the initiation of insulin expression in the endocrine progenitors
by at least two pathways: the formation of insulin-expressing
cells from one pathway requires the function of Pax6 andMafB, while specification of the remaining insulin-expressing
cells may occurs via a Pax4–Hb9 dependent pathway. These
results suggest that MafB can regulate the initiation of insulin
expression in some, but not all, endocrine progenitors destined
to express insulin.
Materials and methods
Construction of expression vectors
Various expression vectors were constructed by conventional molecular
biology techniques. Insulin promoter luciferase reporter constructs −238 WT
LUC and its derivative mutant 121–22m LUC have been described previously
(Harrington and Sharma, 2001). The glucagon promoter luciferase reporter GLU
LUC was kindly provided by Dr. Dan Drucker (Toronto, Canada); the PDX-1
promoter luciferase reporter (Eto et al., 2007), by Dr. Melissa Thomas
(Massachusetts General Hospital, Boston, MA). The expression vectors pcDNA
MafA, pCMVSport6 MafB and pcDNA cMaf have been described previously
(Nishimura et al., 2006). pCMVSport6 krENU expression vector was generated
by PCR amplification of homozygous krENU mouse genomic DNA with
oligonucleotide primers (5′-GACCCGCCAGGACTCACAGAAA-3′and 5′-
CCGCGCAACAGCTACCCACTA-3′) for 35 cycles of 30 sec at 94.0C,
40 sec at 62.3C and 1 min at 72C. PCR product was digested with AflII and
PvuII and was used to replace the corresponding fragment from
pCMVSport6 MafB to give full-length krENU cDNA containing a point
mutation at base pair 743 in the DNA binding region of MafB. Constructs were
confirmed by sequencing.
Luciferase assays
HeLa cells were transfected with 1 μg of reporter constructs of −238 WT
LUC, 121–22 m LUC, GLU LUC or PDX-1 promoter, 1 μg of pSVβ-gal
plasmid (Promega, Madison, WI) as an internal control and 1 μg of indicated
expression vector. Whole cell extracts were prepared and luciferase activity was
measured as previously described (Nishimura et al., 2005).
Animals
Mice with mutation in kreisler/MafB generated by ethylnitrosourea (ENU)
induced chemical mutagenesis have been reported earlier (Cordes and Barsh,
1994). Mutagenesis results in a point mutation in the DNA-binding region of
MafB that changes amino acid 248 from asparagine to serine (krENU orMafBENU)
leading to compromised DNA binding affinity of krENU to Maf Response
Element (MARE)(Sadl et al., 2002). Heterozygous mice with the ENU-induced
krENU allele were received from Dr. Greg Barsh (Stanford, CA), were maintained
on C57Bl/6J background for more than 10 generation and used in this study.
Small eye mutant (Pax6Sey–Neu) mice (Glaser et al., 1994; Hill et al., 1991; Sander
et al., 1997), also generated by chemical mutagenesis, have a point mutation in a
splice donor site of 3′ end of the homeobox that results in incorrect splicing and
truncated Pax6 protein lacking the carboxy-terminal 115 amino acids
corresponding to the transcriptional activation domain. The day of vaginal-
plug discovery was designated as embryonic day E 0.5.
Immunohistochemistry and quantification
Immunohistochemical and immunofluorescent analyses were performed as
described previously (Nishimura et al., 2006). The primary antibodies used
were: guinea pig anti-insulin (Linco, Billerica, MA); guinea pig anti-glucagon
(Linco); rabbit anti-somatostatin (Santa Cruz Biotechnology, CA); rabbit anti-
pancreatic polypeptide (Linco); rabbit anti-Ghrelin (Phoenix Pharmaceuticals,
Belmont, CA); rabbit anti-Hb9 (provided by Dr. S. Pfaff); rabbit anti-MafB
(Bethyl Laboratories, Montgomery, TX); mouse anti-Nkx2.2 (Developmental
Studies Hybridoma Bank, Iowa City, IA); rabbit anti-Nkx6.1 (provided by Dr. P.
Serup); mouse anti-Neurogenin3 (provided by Drs. Serup and Madsen, Beta
Cell Biology Consortium); goat anti-PDX-1 (provided by Dr. C. Wright); rabbit
anti-Pax6 (Covance, Princeton, NJ). Rabbit anti-MafA antibody was described
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anti-mouse or anti-goat antibodies (Jackson ImmunoResearch, West Grove, PA)
were used at a 1:400 dilution followed by streptavidin-conjugated Texas red
(1:400) or streptavidin-conjugated Alexa fluor 488 (1:400) (Molecular Probes,
Eugene, OR). The secondary antibodies were: FITC- or Texas red-conjugated
anti-rabbit, anti-mouse or anti-guinea pig (Jackson ImmunoResearch). Nuclear
counterstaining was performed by DAPI mounting medium (Vector, Burlin-
game, CA). For the double staining using rabbit anti-MafB and rabbit anti-
Ghrelin antibodies, pancreatic sections were first stained with rabbit anti-MafB
antibody using secondary biotinylated anti-rabbit antibody followed by
streptavidin-conjugated Alexa fluor 488, and images of areas expressing
MafB were taken. The same imaged sections were next stained with rabbit anti-
Ghrelin antibody and Texas red conjugated anti-rabbit secondary antibody and
images of the same areas were taken again to examine co-expression of MafB
and Ghrelin. The results of immunohistochemistry and quantification were
derived from several replicates of at least three embryonic pancreases for each
genotype. Every 10th section of embryonic pancreas was analyzed for
immunofluorescent hormone-positive areas as a proportion of epithelial area.
For total number of transcription factor+ cells (for Fig. 2A), every 10th section
was stained with DAB and counted. For number of transcription factor+ insulin+
cells per total number of indicated transcription factor+ cells or total number of
insulin+ cells, cells were counted from at least three different pancreatic blocks.
Immunofluorescence data were collected as confocal images on Zeiss LSM410
(Zeiss, Thornwood, NY); all DAB-stained images were analyzed on an
Olympus BH2 bright field microscope. Images were quantitated using NIH
Image J software.
Western blot analysis
Cell lysates used in luciferase assays were subjected to 10% SDS-PAGE and
gels were transferred to polyvinyldenedifluoride membrane filters (BioRad
Laboratories, Hercules, CA). Western bolt analyses were performed using MafB
and β-actin antibody (Santa Cruz Biotechnology, CA) and detected with
horseradish peroxidase using ECL reagents (Amersham).Results
Pax6 deficiency results in reduced numbers of MafA, MafB and
PDX-1 expressing cells
Previously, we showed that Pax6+ insulin+ cells transition
from a MafB+ MafA− stage to a mature MafA+ MafB−
phenotype (Nishimura et al., 2006). An association between
Pax6 and Maf factors has been reported in different systems
(Reza et al., 2002; Reza and Yasuda, 2004). Pax6 deficiency
results in the inability of endocrine cells to express markers of
terminal differentiation and maturation (Ashery-Padan et al.,
2004). Hence, we examined the role of Pax6 in regulating the
expression and function of Maf factors during pancreatic
development. E15.5 Pax6Sey–Neu/Sey–Neu (subsequently referred
as SeyNeu/SeyNeu) pancreata completely lack Pax6 expressing
cells (antibody recognizes C-terminal domain of Pax6), while
wild type littermates have significant numbers of Pax6+ cells,
some of which co-expressed insulin (Supplementary Fig. 1). As
reported earlier (Sander et al., 1997; Wang et al., 2004), loss of
Pax6 results in a significant reduction in insulin and glucagon-
expressing cells but does not affect the pancreatic expression of
Nkx transcription factors at E15.5. Nkx6.1 expression in the
pancreas marks the area of endocrine differentiation and, as
shown in Supplementary Fig. 1, was unaffected by loss of Pax6
function. Similarly, expression of the pro-endocrine gene Ngn3
was not affected in Pax6 deficient mice (Supplementary Fig. 1),consistent with the earlier observation (Ashery-Padan et al.,
2004; Wang et al., 2004) that Pax6 is not required for the
initiation of endocrine differentiation.
We next examined whether the loss of Pax6 affected the
expression of Maf factors. The number of cells in Pax6-
deficient (SeyNeu/SeyNeu) E15.5 pancreas expressing MafB,
PDX-1 (induced PDX-1 expression during secondary transi-
tion or PDX-1high) and MafA (Figs. 1B–D, F–H) were
reduced. Some cells still expressed these transcription factors
demonstrating the presence of a Pax6 independent mechanism
for their expression. The number of insulin+ cells expressing
these three transcription factors was significantly reduced in
SeyNeu/SeyNeu mice (Figs. 1B–D, F–H). Thus, the loss of
Pax6 function not only reduces the expression of terminal
hormone markers but also reduces the expression of the
transcription factors implicated in the terminal differentiation
process.
We next examined whether expression of MafB, PDX-1high
and MafA were maintained in insulin+ cells in the absence of
Pax6 function (Figs. 1J–L, N–P). As reported previously
(Sander et al., 1997), at E17.5 the number of insulin+ cells
remained low in the SeyNeu/SeyNeu embryos. Additionally,
MafA and PDX-1 expression was restricted to insulin+ cells,
and the number of cells expressing these transcription factors
was reduced (Figs. 1K, L, O, P); most Nkx6.1+ cells expressed
insulin, with only occasional Nkx6.1+ insulin− cells (Figs. 1I,
M). We also observed a greater reduction in insulin+ and MafB+
cells in the SeyNeu/SeyNeu embryos at E17.5 (Fig. 1N) than at
E15.5 (Fig. 1F).
Pax6-deficiency reduces the proportion of MafB+ and
PDX-1high cells expressing insulin
Our observation that MafB+ pancreatic cells are present in
the SeyNeu/SeyNeu embryos (Figs. 1F, N) is consistent with the
conclusion of Artner and colleagues (Artner et al., 2006) that
Pax6 and Pax4 are not essential for MafB expression. To
determine whether Pax6 deficiency reduces only the number of
cells expressing MafB, PDX-1 and MafA or has additional
effects on their function, we quantified stained E15.5 pancreatic
sections (Fig. 2). The number of MafB+ cells was significantly
reduced in SeyNeu/SeyNeu pancreas (Figs. 1F and 2A). While the
number of Nkx6.1+ cells did not change, those of insulin+,
MafB+ and MafA+ cells were reduced by about 75% (Fig. 2A),
clearly demonstrating that loss of Pax6 function significantly
affects MafB+ and MafA+ cells.
Since Pax6 is not required for the specification of endocrine
cells but it regulates their ability to acquire final differentiation
markers (Supplementary Fig. 1, Ashery-Padan et al., 2004;
Heller et al., 2005; Wang et al., 2004), we analyzed in E15.5
pancreas whether the loss of Pax6 expression affected 1) the
ability of MafB+, PDX-1high and MafA+ cells to express insulin
and 2) the ability of remaining insulin+ cells to express normal
levels of these factors. MafA was expressed only in insulin+
cells, while several MafB+ and PDX-1high cells did not express
insulin. Similarly, several insulin+ cells did not express these
transcription factors (Fig. 1). Quantification was performed to
Fig. 1. SeyNeu/SeyNeu embryos have reduced expression MafB, PDX-1 and MafA. Adjacent sections from E15.5 wild type (A–D) and SeyNeu/SeyNeu (E–H) embryonic
pancreata (n=6 each) were stained to detect the expression of Nkx6.1, MafB, PDX-1 and MafA in green and insulin in red. In wild type pancreas adjacent sections
show cells expressing Nkx6.1, MafB, PDX-1 andMafA, but in SeyNeu/SeyNeu embryos MafB, PDX-1 andMafA expression was significantly reduced. E17.5 pancreata
from wild type (I–L) and SeyNeu/SeyNeu (M–P) embryos (n=3 each) were stained for Nkx6.1, MafB, PDX-1 and MafA in green and insulin in red. At this stage loss of
Pax6 function results in significant reduction in the number of insulin+ cells, and the majority of Nkx6.1+, MafB+, PDX-1high and MafA+ cells are restricted to these
insulin+ cells. Bars: 20 μm.
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sing insulin (Fig. 2B) and the proportion of insulin+ cells
expressing different transcription factors (Fig. 2C), as depicted
in the Venn diagrams. Nearly 65–70% of MafB+ cells
(390 MafB+, 273 Ins+ and 259 MafB+Ins+ cells; 259 out of
390), 75–80% of PDX-1high cells (346 PDX-1high, 324 Ins+ and
276 PDX1highIns+ cells) and all MafA+ cells (179 MafA+, 268
Ins+ and 179 MafA+Ins+ cells) expressed insulin in wild type
pancreas whereas loss of Pax6 function significantly reduced
the ability of MafB+ (∼35%)(125 MafB+, 58 Ins+ and
49 MafB+Ins+ cells; 49 out of 125) and PDX-1high (∼45%)
(82 PDX-1high, 58 Ins+ and 49 PDX1highIns+ cells) cells to co-
express insulin. Importantly, while the number of insulin+ cells
was reduced in SeyNeu/SeyNeu pancreas, there was no change inthe proportion of MafA+ cells expressing insulin (100%)
(50 MafA+, 81 Ins+ and 50 MafA+Ins+ cells), which suggests
that MafA is expressed only after insulin+ cells have reached a
latter maturation stage. Next, we quantified the proportion of
insulin+ cells expressing these transcription factors (Fig. 2C).
Unlike the reduction in the proportion of MafB+ and PDX-1high
cells expressing insulin in the absence of Pax6, the proportion
of insulin+ cells expressing these different transcription factors
in wild type and SeyNeu/SeyNeu mice remained unchanged.
Nearly 95%, 75% and 65% of insulin+ cells were MafB+, PDX-
1high and MafA+, respectively, in both wild type and Pax6
deficient mice (Fig. 2C). This observation suggests that the
remaining insulin+ cells derived from a Pax6 independent
pathway appear to undergo normal maturation.
Fig. 2. Pax6-deficiency reduces the proportion of MafB+ and PDX-1+ cells that express insulin. Quantification of immunostained E15.5 embryonic pancreatic sections
from wild type and SeyNeu/SeyNeu embryos (n=6 each). (A) Total number of Nkx6.1+, MafB+ andMafA+ cells in wild type and SeyNeu/SeyNeu embryonic pancreas were
determined along with the number of insulin+ cells in the same sections. In SeyNeu/SeyNeu embryonic pancreas, the numbers of MafB+, MafA+ and insulin+ cells were
significantly reduced (p=0.03, 0.01 and 0.01 respectively), while the number of Nkx6.1+ cells remained unchanged (p=0.46). (B) The ability of transcription factor
expressing cells to express insulin was determined by quantifying the proportion of transcription factor+ insulin+ cells per total number of transcription factor+ cells, as
represented by cells in green circle in adjacent Venn diagram. Proportions of MafB+Ins+ cells/total MafB+ cells and PDX-1+Ins+ cells/total PDX-1+ cells in SeyNeu/
SeyNeu pancreas were significantly less than the wild-type (p=0.005 and 0.01 respectively), while all of the MafA+ cells express insulin. (C) To determine the ability of
insulin+ cells to undergo further maturation in the absence of Pax6 function, the proportion of insulin+ cells expressing these transcription factors was quantified, as
represented by cells in red circle in adjacent Venn diagram. The proportion of MafB+Ins+, PDX-1+Ins+ and MafA+Ins+ cells to the total Ins+ cells was not significantly
different between wild type and SeyNeu/SeyNeu mice.
447W. Nishimura et al. / Developmental Biology 314 (2008) 443–456Pax6 deficiency reduces the proportion of MafB+ cells
expressing glucagon
Since Pax6 deficiency reduced the number of MafB+ cells
that co-express insulin, we also used SeyNeu/SeyNeu mice to
examine whether the MafB+ cells that did not express insulininstead expressed glucagon. At E12.5, Nkx6.1 and PDX-1, two
transcription factors that mark the developing pancreatic
epithelium at this stage, are not expressed in the majority of
glucagon+ cells in either wild type or SeyNeu/SeyNeu pancreas
(Figs. 3A, B, E, F). It is important to note that at E12.5, PDX-1
expression was not affected by Pax6 loss of function. Thus, the
Fig. 3. Pax6-deficiency reduces the proportion of MafB+ cells expressing glucagon. Adjacent sections from E12.5 wild type (A–C) and SeyNeu/SeyNeu (E–G) (n=5
wild type, 4 mutant) pancreata were stained to detect Nkx6.1, PDX-1 and MafB expression in green and glucagon in red. In addition, sections from E15.5 embryonic
pancreata (D, H) were stained for MafB in green and glucagon in red. In E12.5 SeyNeu/SeyNeu pancreata Nkx6.1 and PDX-1 expression was normal, while the
expression of MafB and glucagon expression was reduced at both E12.5 and E15.5. Arrow denotes MafB+ glucagon+ cells in SeyNeu/SeyNeu pancreas at E12.5. Bars:
20 μm. (I) Proportion of MafB+ glucagon+ cells to total number of MafB+ or glucagon+ cells were quantified from wild type and SeyNeu/SeyNeu pancreatic sections from
E12.5 and E15.5. Absence of Pax6 function reduces the proportion of glucagon+ cells that express MafB at both E12.5 and E15.5, while the proportion of MafB+ cells
expressing glucagon is reduced only in E15.5 pancreata.
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may reflect the ability of Pax6 to selectively regulate the
induction of PDX-1 expression (PDX-1high) in insulin+ cells
during secondary transition.
The quantification of glucagon+ and MafB+ cells at E12.5
and 15.5 provides important insights into the roles of Pax6 and
MafB in the induction of hormone expression and in the
differentiation of early endocrine cells. At E12.5 in wild type
pancreas, the majority of MafB+ cells co-express glucagon, and
conversely the majority of glucagon+ cells are MafB+
(260 MafB+, 251 Glu+ and 239 MafB+ Glu+ cells). The
number of MafB+ cells at E12.5 in SeyNeu/SeyNeu pancreata was
extremely low, but all MafB+ cells co-expressed glucagon
(7 MafB+, 37 Glu+ and 7 MafB+ Glu+ cells), and a number of
glucagon+ cells did not express MafB (Fig. 3G). At E15.5, with
the induction of insulin expression, nearly 40% MafB+ cellsexpressed glucagon in wild type (500 MafB+, 204 Glu+ and
198 MafB+ Glu+ cells), and this number decreased to less than
10% in SeyNeu/SeyNeu pancreata (216 MafB+, 48 Glu+ and
15 MafB+ Glu+ cells) (Fig. 3I). Nearly 65% of MafB+ cells at
E15.5 express insulin in wild type pancreas (Fig. 2B),
suggesting that most of the MafB+ cells at E15.5 in wild type
either express insulin or glucagon. Together, these results (Figs.
2 and 3) suggest increased numbers of MafB+ cells that do not
express either insulin or glucagon in SeyNeu/SeyNeu pancreas at
E15.5. Deficiency of Pax6 (Heller et al., 2005) and Nkx2.2
(possibly via reducing Pax6 expression) (Prado et al., 2004)
changes cell-fate of endocrine precursors to ghrelin expressing
ε-cells at the expense of the other endocrine cell types. We
observed a similar increase in ghrelin only expressing ε-cells in
Pax6 deficient mice, but the ghrelin-expressing ε-cells did not
express MafB (Supplementary Fig. 2).
Fig. 4. The krENU allele encodes a reduced ability to activate insulin and glucagon gene expression. (A) Schematics of wild type MafB and its krENU mutant and
deletion derivatives showing activation and DNA binding domains. (B, C) Western blot analyses to detect MafB protein expression from various MafB constructs.
Lysates used in transient transfection assays in panels D and E were subjected to Western blot to detect expression of MafB (B) and β-actin (C). (D) Insulin promoter:
Luciferase reporter constructs, wild type (−238 WT LUC, red) and insulin promoter with mutation in −121–122 bp (−121–122 m LUC, pink), and (E) glucagon
promoter: Luciferase reporter constructs (GLU LUC, green) were transfected into HeLa cells with the indicated expression plasmids and pSVβ-gal as an internal
control. Luciferase and β-gal activities were determined. Results are presented relative to activity of wild-type luciferase construct±S.E. (n=4).
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To determine whether MafB itself plays an important role in
the differentiation of endocrine cells, we first examined the ability
of ENU induced N248S mutation in the MafB coding regionFig. 5.MafB deficiency reduces insulin+ and glucagon+ cells. (A, B) Pancreas from E
embryos were stained for glucagon in green and insulin in red. Immunostained sectio
areas per pancreatic epithelial area as described in Materials and methods. Bars: 20(krENU) to activate the insulin and glucagon promoters. Two
plasmid constructs were made from wild-type MafB plasmid
(pCMV Sport MafB), one carrying the ENU induced N248S
mutation (krENU) and another lacking the C-terminal DNA
binding and bZIP domain (ΔCMafB) (Fig. 4A). All three15.5 wild type (+/+) and MafB mutant (krENU/krENU) (n=4 wild type, 4 mutant)
ns were used to quantify the proportion of insulin (C) and glucagon (D) positive
μm.
Fig. 6. MafB deficiency does not inhibit the initiation of endocrine differentiation. Sections from E15.5 pancreata from wild type and krENU/krENU embryos were
stained for Ngn3, Nkx2.2 and Pax6 in green and insulin in red. Expression of insulin was reduced in krENU/krENU pancreata, but Ngn3, Nkx2.2 and Pax6 expression
was similar to that in the wild type embryos. Bars: 20 μm.
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recognized by anti-MafB antibody in Western blots (Fig. 4B).
Quantification with normalization to β-actin (Fig. 4C) indicated
that krENU is expressed at a level slightly higher than the wild-
typeMafB protein. Co-transfection of these plasmids with insulin
(Fig. 4D) or glucagon (Fig. 4E) promoter luciferase reporter
constructs demonstrated that wild type MafB activated both
insulin and glucagon promoters, as previously reported (Nishi-
mura et al., 2006; Zhao et al., 2005).ΔCMafB was ineffective in
inducing expression of these genes, and krENU showed significant
impairment in its ability to activate insulin and glucagon gene
expression (Figs. 4D, E). Co-transfecting these expression
plasmids with the insulin reporter construct −122.121 m Luc
(Harrington and Sharma, 2001) containing a mutated insulin
MARE significantly reduced the MafB and krENU mediated
activation of luciferase, suggesting that krENU retains some
residual activity to regulate insulin expression via its cognate
binding site. Thus, in principal, krENU mice should represent a
model of MafB deficiency, but not absence, of MafB function.
MafB deficiency results in reduction of insulin+ and glucagon+
cells
In adult mouse pancreas MafB expression is restricted to α-
cells, but during embryonic development MafB expression isFig. 7. MafB deficiency reduces PDX-1, MafA and insulin expression and impair
sections from E15.5 wild type and krENU/krENU (n=4 wild type, 3 mutant) pancreata
In krENU/krENU sections the number of cells expressing PDX-1, MafA and insulin w
pancreatic sections from wild type and krENU/krENU embryos were quantified to dete
proportion of insulin+ cells expressing different transcription factors (J). (I) Propor
cells in krENU/krENU were significantly reduced, while all MafA+ cells expressed ins
not significantly different between wild type and krENU/krENU. (K) MafB and other
luciferase reporter construct was transfected into HeLa cells with the indicated ex
presented relative to the activity of a wild-type luciferase construct transfected witalso seen in insulin+ cells (Nishimura et al., 2006). Since our
results indicate a correlation between reduced MafB expression
and the number of insulin+ and glucagon+ cells in SeyNeu/
SeyNeu mice (Figs. 1–3), we hypothesized that MafB might
regulate the differentiation of both α- and β-cells. To test this
hypothesis we examined the effect of MafB deficiency on
endocrine differentiation using krENU/krENU mice. At E15.5,
MafB deficiency did not affect pancreatic appearance but
insulin+ and glucagon+ cells were drastically reduced (Figs. 5A,
B). As a percentage of total epithelial area, insulin+ and
glucagon+ area were reduced to nearly 55% and 60%,
respectively (Figs. 5C, D). Thus, as in SeyNeu/SeyNeu mice,
MafB deficiency results in a reduction, but not complete loss, of
insulin+ and glucagon+ cells.
MafB deficiency does not affect the initiation of endocrine
differentiation
We next examined the mechanism underlying the reduced
number of insulin+ and glucagon+ cells in krENU/krENU mice.
During pancreatic development, the transcription factor Ngn3
marks the progenitors that give rise to endocrine cells, while
Pax6 marks cells further along the endocrine differentiation
pathway. Nkx2.2 is expressed in early epithelial progenitors and
subsequently becomes restricted to endocrine cells. Pancreatics the ability of MafB+ and PDX-1+ cells to express insulin. (A–H) Adjacent
were stained for MafB, Nkx6.1, PDX-1 and MafA in green and insulin in red.
ere reduced compared to wild type pancreata. Bars: 20 μm. (I, J) Stained E15.5
rmine the proportion of transcription factor+ cells expressing insulin (I), and the
tions of MafB+Ins+ cells/total MafB+ cells and PDX-1+Ins+ cells/total PDX-1+
ulin. (J) The proportion of insulin+ cells expressing MafB, PDX-1 or MafAwas
large Maf factors can activate PDX-1 expression. A −4.5 kb PDX-1 promoter:
pression plasmids and pSVβ-gal was used as an internal control. Results are
h the pcDNA3.1±S.E. (n=3).
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immunostained for Ngn3, Nkx2.2 and Pax6 (Fig. 6). Although
krENU/krENU mice have reduced insulin+ cells, the number of
Ngn3+ cells was unaffected (Figs. 6A, D), suggesting thatMafBdeficiency does not affect the specification of endocrine
differentiation. Similarly, MafB deficiency did not affect
Nkx2.2+ or Pax6+ cell number (Figs. 6B, C, E, F). These
results show that the krENU mutation does not affect pancreatic
Fig. 8. MafB deficiency does not induce the formation of ε-cells. Sections from
E15.5 wild type (+/+) and krENU/krENU pancreata were stained to detect
somatostatin (Som) or ghrelin (Ghre) in green and a mixture of antibodies that
recognize insulin and glucagon in red. In spite of reduction in the number of
insulin and glucagon expressing cells, the number of somatostatin+ and ghrelin+
cells is unchanged in krENU/krENU embryos. Also, ghrelin+ glucagon− ε-cell
numbers were similar in pancreata from wild type and krENU/krENU embryos.
452 W. Nishimura et al. / Developmental Biology 314 (2008) 443–456precursors or formation of endocrine cells and that the reduction
in the number of insulin+ and glucagon+ cells (Figs. 5 and 6)
occurs in the absence of any change in the levels of Pax6+ cells
(Figs. 6C, F).
Effect of MafB deficiency on MafB+, PDX-1high and MafA+
cells
Whether the homozygous krENU mutation affected the
maturation of insulin+ cells was addressed next. Since the kr-
allele expresses a mutant protein recognized by the MafB
antibody (Fig. 4B), we examined the effect of MafB deficiency
on MafB expression. In the krENU/krENU pancreas at E15.5
Nkx6.1+ cells were not affected by MafB deficiency (Figs. 7B,
F), insulin+ MafB+, insulin− MafB+ cells and occasional
insulin+ MafB− cells were seen, and the total number of
MafB+ cells showed a modest increase (∼20%) compared to the
wild type (Figs. 7A, E). Unlike the effect ofMafB deficiency on
its own expression, the number of PDX-1high and MafA+ cells
were reduced (Figs. 7C, D, G, H), suggesting that deficient
MafB function was sufficient to reduce, but not eliminate,
cells expressing PDX-1high and MafA. At E15.5, nearly 60% of
MafB+ cells (175 MafB+, 110 Ins+ and 105 MafB+Ins+ cells)
expressed insulin in wild type, but this number dropped to
∼25% in krENU/krENU (238 MafB+, 68 Ins+ and 65 MafB+Ins+
cells) (Fig. 7I). This observation suggests that a functionally
compromised MafB isoform (krENU) prevents a significant
proportion of differentiating endocrine cells from expressing
insulin. The deficiency of MafB function also resulted in a
reduced proportion of PDX-1high cells co-expressing insulin
(128 PDX-1high, 122 Ins+ and 92 PDX1highIns+ cells in wild
type vs. 107 PDX-1high, 90 Ins+ and 65 PDX1highIns+ cells in
krENU/krENU pancreas). This reduced ability of MafB+ and
PDX-1high cells to co-express insulin in MafB deficient mice
was similar to that observed in SeyNeu/SeyNeu mice (Fig. 2). In
krENU/krENU pancreas all MafA+ cells were insulin+, but not all
insulin+ cells expressed MafA (75 MafA+, 111 Ins+ and
75 MafA+Ins+ cells in wild type vs. 60 MafA+, 92 Ins+ and
60 MafA+Ins+ cells krENU/krENU pancreas). Interestingly, the
proportion of insulin+ cells co-expressing the different tran-
scription factors was unaltered in wild type and krENU/krENU
mice (Fig. 7J): nearly 95%, 75% and 65% of insulin+ cells co-
expressed MafB, PDX-1high and MafA, respectively.
The ability of MafB to directly activate PDX-1 expression
was examined by co-transfecting −4.5 kb PDX-1:luciferase
plasmid (Eto et al., 2007) and either MafA, MafB or cMaf
plasmids in HeLa cells (Fig. 7K). MafA, MafB and cMaf were
all capable of activating PDX-1 expression, consistent with the
reported ability of MafA to induce PDX-1 expression (Samaras
et al., 2003).
Unlike Pax6, MafB deficiency does not affect the cell-fate
decision of endocrine cells
As stated above, SeyNeu/SeyNeu and krENU/krENU mice show
very similar pattern of reductions of insulin+ and glucagon+
cells. Loss of Pax6 function results in endocrine cells that donot express insulin or glucagon and that acquire an alternate
cell-fate with ghrelin expression (Prado et al., 2004; Heller et
al., 2005). However, in E15.5 krENU/krENU the reduction in
insulin+ and glucagon+ cells was not accompanied by an
increase in somatostatin+ or ghrelin+ cells (Fig. 8 and Artner et
al., 2007). This finding is consistent with our observation in
SeyNeu/SeyNeu mice that the ghrelin+ ε cells do not express
MafB (Supplementary Fig. 2). Thus, MafB deficiency, unlike
Pax6 deficiency, does not trigger endocrine cells to acquire
alternate cell-fates.
An increased proportion of the remaining insulin+ cells in
krENU/krENU pancreata express Hb9
The presence of insulin+ and glucagon+ cells in SeyNeu/
SeyNeu and krENU/krENU mice suggests the induction of these
hormones can occur via a pathway independent of Pax6 or
MafB function. Two parallel pathways have been proposed to
trigger the formation of insulin+ cells: one involving Nkx2.2 and
Pax4 in regulating the Hb9 and PDX-1 dependent expression of
insulin, and a second involving Nkx2.2, Pax6 and PDX-1
(Wang et al., 2004). Wang and colleagues reported that at E14.5,
Pax6 deficiency had no obvious effect on Hb9 expression; we
also observed cells expressing Hb9 in our Pax6 deficient mice at
E15.5 (Supplementary Fig. 3). Since our data suggest thatMafB
functions downstream of Pax6, we examined whether MafB
deficiency differentially affected the formation of insulin+ cells
from either the Nkx2.2–Pax6 or Pax4–Hb9 pathways by
quantifying immunostained E15.5 wild type and krENU/krENU
pancreata. Here, MafB deficiency increased the proportion of
insulin+ cells expressing Hb9 but had no effect on the ability of
Fig. 9. An increased proportion of insulin+ cells in the MafB deficient pancreata
co-express Hb9. (A, B) E15.5 sections from wild type and krENU/krENU
pancreata were stained for Hb9 in green and insulin in red. Hb9− insulin+ cells
and Hb9+ insulin+ cells co-exist in the wild type pancreas while the number of
Hb9− insulin+ cells is reduced in krENU/krENU pancreas. Bars: 20 μm. (C)
Quantification of immunohistochemical data. The proportion of Hb9+ cells
expressing insulin did not change between the krENU/krENU and wild type mice.
However, the proportion of insulin+ cells that co-express Hb9 in these mice is
significantly increased (p=0.02).
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Hb9+Ins+ cells in wild type vs. 139 Hb9+, 111 Ins+ and 104
Hb9+Ins+ cells krENU/krENU pancreas) (Fig. 9). The increased
proportion of insulin+ cells expressing Hb9 in krENU/krENU
mice suggests that these remaining insulin+ cells may be
specified via the Pax4–Hb9 pathway.
Discussion
Previously we proposed that the maturation of insulin+ cells
during embryonic development requires a switch from an
insulin+ MafB+ state to an insulin+ MafA+ state via an
intermediate PDX-1high stage. Here we use Pax6 and MafB
deficient mice to demonstrate that the deficiency of either Pax6
or MafB function results in reduced number of cells expressing
insulin, glucagon, PDX-1 and MafA (Figs. 1, 3, 5, 7).
Comparable proportions of Ngn3 and MafB expressing cells
in krENU/krENU and wild type pancreata (Figs. 6 and 7) suggest
that similar to Pax6 deficiency (Ashery-Padan et al., 2004),
MafB deficiency does not affect the initiation of endocrinedifferentiation, but affects expression of markers of terminal
differentiation. The reduced function of either Pax6 or MafB
results in an increased proportion of MafB+ insulin− and PDX-
1high insulin− cells, while the expression of MafA, although
reduced, is always restricted to the cells that express insulin
(Figs. 2 and 7), suggesting that PDX-1 and MafA function
downstream of Pax6 and MafB. The loss of Pax6 function
reduces the numbers of MafB expressing cells (Figs. 1 and 2),
while the deficiency of MafB activity has no effect on Pax6
expression (Fig. 6). Taken together, these results suggest that
MafB can be a downstream mediator of Pax6 function or that
Pax6 requires MafB for inducing the expression of insulin and
glucagon. However, the conversion of endocrine precursors into
ghrelin+ cells does not occur inMafB deficient mice (Fig. 8, and
Artner et al., 2007) as observed in the absence of Pax6 function
(Heller et al., 2005; Prado et al., 2004, and Supplemenraty Fig.
2). Thus, the suppression of ghrelin+ ε-cells occurs at the level
of Pax6 expression, and MafB does not appear to have a direct
role in regulating the formation of ε-cells.
Analysis of Nkx2.2, Pax6 and Pax4 knockout mice
suggested that specification of insulin+ cells involves two
distinct pathways; one requiring Nkx2.2, Pax4, Hb9 and PDX-
1, and a second involving Nkx2.2, Pax6 and PDX-1 (Wang et
al., 2004). Deficiency of MafB function in krENU/krENU mice
led to reduction of insulin+ and glucagon+ cells (Fig. 5) as in
Pax6 deficient mice (Sander et al., 1997; Wang et al., 2004;
Ashery-Padan et al., 2004; Figs. 1 and 3). These observations
suggest that insulin and glucagon expression in some endocrine
precursors is independent of Pax6 andMafB function. A similar
reduction in the proportion of hormone+ cells found in MafB
knockout mice (Artner et al., 2007) suggests that the residual
activity of the krENU allele does not regulate the formation of
remaining hormone+ cells. We also observed in MafB deficient
mice an increased proportion of remaining insulin+ cells
expressing Hb9 (Fig. 9). This increase could be due to the
selective lack of insulin+ cells derived from the Pax6–MafB
pathway in these krENU/krENU mice. Thus, our results provide
strong support to the two parallel pathways model proposed by
Sosa-Pineda and colleagues for the formation of insulin+ cells
(Wang et al., 2004).
The presence of increased numbers of MafB+ insulin− cells
in SeyNeu/SeyNeu mice (Fig. 2) suggests that either Pax6
function is essential for MafB to activate insulin expression or
Pax6 initiates insulin expression with MafB required for further
maturation of insulin+ cells. However, in krENU/krENU mice the
number of Pax6+ cells was unchanged while that of insulin+
cells was reduced (Fig. 6). Thus, it is most likely that in the
presence of Pax6 (or following its action), MafB initiates the
expression of insulin in some hormone− endocrine precursors.
Although Pax6 andMafB are required for the formation of only
some insulin+ cells, they are expressed in most, if not all,
insulin+ cells, suggesting a role for these factors even in insulin+
cells derived from a Pax6–MafB independent pathway. Since
maturation of insulin+ cells accompanies their transition from
MafB to MafA expression (Nishimura et al., 2006), MafB may
have two distinct roles during endocrine differentiation: one
essential for regulating the differentiation of insulin+ cells via
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Pax4–Hb9 derived insulin+ cells. Additional studies are needed
to confirm the consequence of a loss of MafB or Pax6 function
on the maturation of these latter insulin+ cells.
The increased proportion of insulin+ Hb9+ cells in krENU/
krENU mice would suggest that the induction of insulin
expression in the Pax4–Hb9 pathway does not depend on
MafB expression. Interestingly, a recent MafB knockout study
(Artner et al., 2007) suggested that MafA was required to
specify the remaining insulin+ cells. However, since MafA is
expressed only in insulin+ cells in krENU/krENU mice and many
insulin+ cells are MafA− (Fig. 7), it is unlikely that MafA
induces insulin expression in MafB knockout mice. MafA, at
the most, might be responsible for a subpopulation of insulin+
cells (MafA+ cells), while another factor is required to trigger
insulin expression in MafA− cells. It is important to note that
MafA expression remained restricted to insulin+ cells in both
SeyNeu/SeyNeu and krENU/krENU mice, and MafA knockout mice
(Zhang et al., 2005) show no reduction in insulin+ cells at birth.
It seems most likely that MafA expression is initiated only after
the induction of insulin expression in endocrine precursors,
which suggests that in krENU/krENU mice a factor other than
MafA or MafB induces insulin expression in cells differentiat-
ing via the Pax4–Hb9 pathway. While our analysis of MafB
deficient mice generally agrees with a recent characterization of
MafB knockout mice (Artner et al., 2007), our data do not
support a role for PDX-1high upstream of MafB function nor a
role for MafA in inducing insulin expression. Additionally, by
analyzing bothMafB and Pax6 deficient mice, the current study
extends our understanding of the role of MafB in pancreatic
development. Our results strongly suggest that MafB functions
downstream of Pax6 and is most likely responsible for the Pax6
dependent loss of insulin+ and glucagon+ cells.
Analysis of SeyNeu/SeyNeu mice demonstrates a role of Pax6
andMafB in the differentiation of glucagon+ cells. The majority
of glucagon positive cells present before the secondary
transition express MafB (Fig. 3), consistent with the expression
of Pax6 in the early glucagon+ cells reported earlier (Heller et
al., 2004; Sander et al., 1997). It is likely that the MafB+
glucagon− cells present at E12.5 (Fig. 3) represent the insulin+
MafB+ cells seen at this stage (Nishimura et al., 2006). At
E15.5, due to the increase in insulin+ MafB+ cells, the
proportion of MafB+ cells expressing glucagon decreased.
Yet, the proportion of glucagon+ cells expressing MafB
remained unchanged at 95% in wild type mice (Figs. 2 and
3), suggesting that either the induction of glucagon expression
in a small proportion of endocrine precursors in wild type mice
does not require MafB function or that MafB is turned on
rapidly after the induction of glucagon.
Loss of Pax6 function significantly reduced the number of
MafB+ cells, resulting in a significant proportion of glucagon+
cells not expressing MafB at both E12.5 and E15.5 (Fig. 3).
This finding suggests either the existence of a Pax6–MafB
independent pathway for the induction of glucagon or a lack of
sustainability of MafB in these glucagon+ cells in the absence of
Pax6 function. The reduction in the proportion of glucagon+
cells expressing MafB in SeyNeu/SeyNeu mice was opposite ofno effect of Pax6 deficiency on the ability of insulin+ cells to
express MafB (Figs. 2 and 3). This observation suggests
differences in the specification and maturation of glucagon+
cells and insulin+ cells. Since the specification and maturation
process of glucagon+ cells does not require the function of
PDX-1 and MafA, it is likely that MafB does not regulate the
maturation process and only regulates initiation of glucagon
expression. A recent study showing different actions of Nkx2.2
in rescuing glucagon and insulin-expressing cells in Nkx2.2
knockout mice (Doyle et al., 2007), supports the suggestion that
the transcription factors that regulate differentiation of both
insulin and glucagon expression, use distinct mechanisms in
each endocrine cell type. Similarly,MafB may only be involved
in specification of glucagon+ cells whereas it may have a dual
role in the specification and maturation of insulin+ cells.
Inhibiting the proper maturation of insulin+ cells has
functional consequences. It has been shown thatMafA knockout
mice develop diabetes due to postnatal reduction in β-cell
number (Zhang et al., 2005). Inhibition of MafA function in
insulin-producing cells via gene knock-down also resulted in
reduced expression of genes involved in insulin synthesis and
secretion (Wang et al., 2007). MafA regulates the expression of
granuphilin, critical for docking the insulin vesicle to the plasma
membrane (Kato et al., 2006). Furthermore, insulin+ cells
derived from human embryonic stem cells expressed MafB but
not PDX-1 and probably not MafA (D'Amour et al., 2006); this
lack could contribute to their inability to secrete insulin in
response to glucose and further highlights the importance of the
maturation process.
Previously we proposed that during maturation, insulin+
cells undergo a switch from an insulin+ MafB+ state to an
insulin+ MafA+ state via an intermediate PDX-1high stage. In
this study, we observed that nearly 95%, 75% and 65% of
insulin+ cells in wild type, SeyNeu/SeyNeu, and krENU/krENU
mice expressed MafB, PDX-1 and MafA, respectively (Figs. 2
and 7). The observed gradation in expression of these three
transcription factors in insulin+ cells as well as the ability of
MafB to activate PDX-1 expression further supports our
hypothesis that maturation of insulin+ cells proceeds from a
MafB+ to MafA+ state after the induction of PDX-1high. Results
from Pax6 and MafB deficient mice further support such
sequential requirement forMafB, PDX-1 and MafA functions in
the maturation process. An analysis of conditional PDX-1
knockout in developing endocrine cells will be necessary to
confirm whether the MafB is upstream of PDX-1high function
andMafA is downstream of this gene. Knowledge of the precise
function of these transcription factors during the maturation of
insulin+ cells will play a crucial role in generating glucose
responsive insulin producing cells.
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